Ars Pharmaceuticals Inc (SPRY)

$SPRY $NDAQ $RUT @Stocktwits Recent trading suggests short-term price movement is being driven more by off-exchange activity via dark pools, ATS desks, and broker internalization than by changes in fundamentals. When a large share of volume occurs away from lit markets, visible price discovery can lag, which appears to be happening here. Institutional and insider ownership exceeds 90%, leaving a highly constrained effective float. In this structure, relatively modest positioning flows-particularly short activity routed through dark pools/ATS desks/brokers - can delay and suppress price without reflecting genuine selling. There is little evidence of distribution by long-term institutions or retail investors. Borrow conditions have remained CHEAP for an extended period, but as Neffy’s competitive position strengthens and competing needle-free alternatives remain delayed 12+ months, the cost and risk of maintaining short borrow exposure should RISE materially. A failure of BORROW FEES to increase from here would be HIGHLY UNUSUAL given SPRY’s RECENT REGULATORY ACHIEVEMENTS, upcoming approvals and overall business trajectory. SPRY remains a float-constrained stock where price discovery appears suppressed and delayed, not broken. With growing sales momentum and multiple recent/upcoming regulatory milestones, A BORROW FEE SPIKE SHOULD BE INCOMING. In turn this should re price UP in the coming months!

$AQST buyout coming. Slam dunk drug to put $SPRY out of business and the epi pen. Can’t wait to carry this

$AQST Neffy sales have been very poor and the stock is valued at 1 billion dollars (!!)... That's why shorts are loaded to the tits in $SPRY

H.C. Wainwright reiterated $AQST Buy/$10 $SPRY $NSRX $TEVA $VTRS Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2018676414778630511?s=20

$SPRY I don't understand the $AQST cult. JFC, delay of 2 years and they are all jabbering like the won the lottery. Dan sefra is writing ai dream pieces about how they will get OTC on the approval. Biotech scammer is going around calling patients in the trials morons. ARS has 2 years to dominate, and the rate of sales growth has not been impressive. The company needs to get Dr.'s who have written generic epi for decades to change what they know works. It takes a hesitant dr to write it once, get feed back that it works before they are comfortable. We are near or at that point. I think I see green shoots in symphony scripts 4q. It's an earnings growth story from here. All I know is I'd rather own spry at a 1b cap, with some sales that are scaling and 1st to market advantage of 2 years, than aquestive with a 500m cap with delay &dilution.

$AQST now you can understand why $SPRY short interest remained sky high and it barely budged on this CRL -- because this CRL was not that and because neffy sales have been horrible.

$SPRY $AQST Catch up with me if you can! Q2 27 approval if it ever happens would not change the financial fortunes of aqst company. Too little too late

$SPRY update from Raymond James. Remains Strong Buy on Favorite Stock List and price target increase from $32 to $34.

$SPRY @stone52 comes up with more rubbish that does not make sense with aqst... stick to your own ticker